Table 1.
Characterization of kidney group 2 innate lymphoid cells (ILC2s).
| Species | ILC Subsets (Markers) | Characteristics | Tissue Localization | Reference |
|---|---|---|---|---|
| Human | Total ILCs (Lin-CD127+CD161+); ILC2s (Lin-CD127+CD161+CRTH2+); ILC3s (NKp44+, and NKp44-CRTH2-CD117+); ILC1s (CRTH2-CD117-NKp44-) | * ILC3 constitute ~55% of total ILCs; * ILC2 constitute ~30% of total ILCs; * ILC1 constitute ~10% of total ILCs | Riedel et al. [48] | |
| Mouse | ILC2s CD45+Lin-CD127+CD90.2+ST2+ | *Kidney ILC2s constitutively express IL-5 | IL-5+ILC2s localize the major vasculature in healthy kidney | Cameron et al. [59] |
| Mouse | ILC2s (CD45+Lin-CD127+GATA3+ | * Mouse ILC2s constitute ~80% of total ILC2s | ILC2s localized in glomerular and tubulointerstitial compartments | Riedel et al. [48] |
| Mouse | ILC2s (CD45+Lin-CD127+GATA3+ST2+) | * IRI alone did not altered ILC2s | Cao et al. [49] | |
| * Exogenous IL-33 expands ILC2s | ||||
| Mouse | ILC2s (CD45+Lin-ST2+) | * Adoptive transfer of ex vivo expanded spleen-derived ILC2s by IL-233 hybrid protects the against IRI | Stremska et al. [51] | |
| Mouse | ILC2s (CD45+Lin-ST2+CD90+) | * IL233 expands spleen and kidney ILC2s | Sabapathy et al. [50] | |
| Mouse | ILC2s (CD45+Lin-CD90.2+ GATA3+) |
* Mouse ILC2s constitute ~70% of total ILCs; | Chen et al. [58] | |
| * ILC2s were expended 2 fold following UUO |
ILC, innate lymphoid cells; CRTH2, chemoattractant receptor-homologous molecule expressed on TH2 cells; Lin, lineage, GATA3, GATA binding protein 3; IRI, ischemia-reperfusion injury.